Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.230
+0.030 (2.49%)
Sep 22, 2026, 1:23 PM EDT - Market open
Marker Therapeutics Employees
Marker Therapeutics had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$709,334
Profits / Employee
-$1,741,476
Market Cap
20.51M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | -59 | -88.06% |
| Dec 31, 2022 | 67 | 11 | 19.64% |
| Dec 31, 2021 | 56 | 12 | 27.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Palatin Technologies | 29 |
| Jasper Therapeutics | 22 |
| Lantern Pharma | 16 |
| Lipocine | 14 |
| NewcelX | 12 |
| Tvardi Therapeutics | 12 |
| Neuphoria Therapeutics | 8 |
MRKR News
- 5 hours ago - Marker Therapeutics highlights expanded manufacturing support of CDMO partner - TheFly
- 6 hours ago - Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Quarterly report: Q2 2026 - Filings
- 4 months ago - Marker Therapeutics Quarterly report: Q1 2026 - Filings
- 6 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 6 months ago - Marker Therapeutics Proxy statement: Proxy filing - Filings
- 6 months ago - Marker Therapeutics reports FY25 EPS (79c), two estimates (94c) - TheFly
- 6 months ago - Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewsWire